Ryvu Therapeutics S.A.

WSE:RVU Stock Report

Market Cap: zł1.2b

Ryvu Therapeutics Future Growth

Future criteria checks 1/6

Ryvu Therapeutics's earnings are forecast to decline at 16.3% per annum while its annual revenue is expected to grow at 13.5% per year.

Key information

-16.3%

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth25.5%
Revenue growth rate13.5%
Future return on equityn/a
Analyst coverage

Low

Last updated29 May 2024

Recent future growth updates

Recent updates

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Oct 20
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Aug 02
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Jan 25
Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Feb 05
What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Dec 14
Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Earnings and Revenue Growth Forecasts

WSE:RVU - Analysts future estimates and past financials data (PLN Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202686-176-92-1711
12/31/2025132-140-100-1482
12/31/202491-162-162-1511
3/31/202474-94-103-95N/A
12/31/202367-92-93-85N/A
9/30/202384-73-60N/A
6/30/202388-66-23N/A
3/31/202380-75410N/A
12/31/202268-841521N/A
9/30/202250-94-51-44N/A
6/30/202237-105-68-58N/A
3/31/202236-92-80-69N/A
12/31/202135-79-71-59N/A
9/30/202126-72-74-58N/A
6/30/202125-61-61-37N/A
3/31/202130-41-38-5N/A
12/31/202037-32-45-11N/A
9/30/202038-40-57-23N/A
6/30/202041-32-74-51N/A
3/31/202017-41-36-17N/A
12/31/201934-44-41-17N/A
9/30/201953-53-55-27N/A
6/30/201919-60-38-6N/A
3/31/2019116-28-77-49N/A
12/31/201852-23-44-26N/A
9/30/2018492-22-7N/A
6/30/20189614-19-4N/A
3/31/201810221422N/A
12/31/20171056N/A11N/A
9/30/201710413N/A7N/A
6/30/20179714N/A8N/A
3/31/20178010N/A-24N/A
12/31/2016663N/A-6N/A
9/30/2016600N/A-6N/A
6/30/201660-1N/A-10N/A
3/31/2016573N/A-14N/A
12/31/2015566N/A-16N/A
9/30/2015517N/A-10N/A
6/30/2015487N/A-8N/A
3/31/2015467N/A-5N/A
12/31/2014416N/A-5N/A
9/30/2014434N/A-6N/A
6/30/2014352N/A-5N/A
3/31/201427-1N/A-6N/A
12/31/201322-2N/A-7N/A
9/30/201310-5N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RVU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RVU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RVU's revenue (13.5% per year) is forecast to grow faster than the Polish market (4.4% per year).

High Growth Revenue: RVU's revenue (13.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RVU's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y